... of NSCLC in terms of etiopathogenesis and tumor biology. Since the introduction of the reversible EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, patients with metastatic EGFR mutation-positive lung cancer can be offered a therapeutic alternative that has proven its superiority over...

...Sven Bontognali; Miklos Pless; Martin H. Brutsche; Claude Fischer; Christoph Rochlitz; Martin Buess Background: The efficacy of chemotherapy in metastatic and recurrent squamous cell carcinomas of the head and neck (HNSCC) remains unsatisfactory. Gefitinib offers a new therapeutic option...

...Jing Chen; Runxia Gu; Qiong Wang; Meera Dassarath; Zhongyuan Yin; Kunyu Yang; Gang Wu Background: Although epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitors (TKIs) are widely used in the management of advanced non-small cell lung cancer (NSCLC), gefitinib-induced...

... and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK...

...Haruhiro Saito; Shuji Murakami; Tetsuro Kondo; Fumihiro Oshita; Kazumasa Noda; Kouzo Yamada Background: There have been reports on the use of erlotinib in non-small cell lung cancer (NSCLC) patients after gefitinib resistance occurs, and it has been stated that erlotinib may be beneficial...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. EGFR Mutation Gefitinib...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Non-small cell lung cancer NSCLC Survival Epidermal growth factor receptor EGFR Gefitinib Second primary tumour...

... feasibility of front-line administration of gefitinib for the treatment of non-small cell lung carcinomas (NSCLCs) harboring intragenic epidermal growth factor receptor (EGFR) mutations. The experience of the use of this EGFR tyrosine kinase inhibitor (TKI) in non-Asian subjects remains limited. Patients...

...Tanja Trarbach; Anke Reinacher-Schick; Susanne Hegewisch-Becker; Udo Vanhoefer; Thomas Frieling; Lasse Lehnert; Wolff Schmiegel; Ullrich Graeven Background: This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib...

... (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib. Case Reports: We present the follow-up data of 2 EGFR mutation-positive stage IV NSCLC patients who received upfront 250 mg gefitinib daily, then underwent potentially curative surgery, and resumed gefitinib therapy in the adjuvant...

...Jörg Thomas Hartmann; Jan Peter Pintoffl; Hendrik Kröning; Carsten Bokemeyer; Martin Holtmann; Thomas Höhler Background: The aim of the study was to establish the recommended dose and to evaluate the safety of gefitinib plus FUFOX regimen in irinotecan-refractory colorectal carcinoma (CRC...

...Zhen Wang; Yi Long Wu; Guo Chun Zhang; Qing Zhou; Chong Rui Xu; Ai Lin Guo Background: For gefitinib treatment for non-small cell lung cancer (NSCLC), KRAS mutations reportedly behave as a resistance marker, and the epidermal growth factor receptor (EGFR) as a responsive marker. It is known...